


Public Health Service





APR 23 1999

The Honorable O. Todd Dickinson Deputy Assistant Commissioner for Patent Policy and Projects Office of the Assistant Commissioner for Patents U.S. Patent and Trademark Office Crystal Park Building 2, Suite 919 Washington, DC 20231

RECEIVED

Ark & 9 1777

SPECIAL PROGRESSING STRICE DAC FOR PATENTS

Food and Drug Administration Rockville MD 20857

> Re: ALDARA Docket No. 97E-0269 Docket No. 97E-0270

Dear Commissioner Dickinson:

This is in regard to the patent term extension applications for U.S. Patent Numbers. 5,238,944 and 4,689,338 filed by Riker Laboratories under 35 U.S.C. § 156. The patents claim the human drug product ALDARA<sup>™</sup> (imiquimod), new drug application NDA 20-723.

In the October 20, 1998 and October 15, 1998, issues of the Federal Register (63 Fed. Reg. 56035 and 55398), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notices provided that on or before April 19, 1999, and April 13, 1999, 180 days after the publications of the determinations, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day periods for filing a due diligence petition pursuant to these notices have expired and FDA has received no such petitions. Therefore, FDA considers the regulatory review period determinations to be final.

Please let me know if we can provide further assistance.

Sincerely yours.

Ronald L. Wilson, Director Health Assessment Policy Staff

Office of Health Affairs

Ted K. Ringsred CC:

3M/Office of Intellectual Property Counsel

P.O. Box 33427

St. Paul, MN 55133-3427